Technology

Kiniksa Pharmaceuticals

$18.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.80 (+4.58%) Today
-$0.26 (-1.42%) As of 11:17 AM UTC after-hours

Why Robinhood?

You can buy or sell KNSA and other stocks, options, and ETFs commission-free!

About KNSA

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda. The listed name for KNSA is Kiniksa Pharmaceuticals, Ltd. Class A Common Stock.

CEO
Sanj K. Patel
Employees
137
Headquarters
Hamilton, Hamilton
Founded
2015
Market Cap
1.33B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
328.60K
High Today
$18.35
Low Today
$16.85
Open Price
$17.21
Volume
320.79K
52 Week High
$28.67
52 Week Low
$10.30

Collections

KNSA Earnings

-$0.72
-$0.48
-$0.24
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, Pre-Market

You May Also Like

AGGP
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure